Gilead Sciences, Inc.
GILD Healthcare Drug Manufacturers General
Gilead Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $29.4 billion, up 2.40% from fiscal 2024. In the quarter to June 2026, revenue grew 10.2%, EPS fell 638.2%, free cash flow grew 376.8% and total debt rose 5.21%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; dividend growth for ten consecutive years.
Follow GILD
Gilead Sciences, Inc. (GILD) Total debt
Gilead Sciences, Inc.'s total debt at the end of fiscal 2025 was $24.9B, down 6.65% from $26.7B in fiscal 2024. At the end of the quarter to 30 June 2026 it was $26.2B. Over the past ten years it has ranged from $22.5B (fiscal 2015) to $34.1B (fiscal 2017); the current reading is higher than 18% of that period. Gilead Sciences, Inc. ranks 10th of 21 Drug Manufacturers General companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $24.9B | (6.65%) |
| FY2024 | $26.7B | 1.69% |
| FY2023 | $26.3B | (0.54%) |
| FY2022 | $26.4B | (4.56%) |
| FY2021 | $27.7B | (15.16%) |
| FY2020 | $32.6B | 27.40% |
| FY2019 | $25.6B | (9.73%) |
| FY2018 | $28.4B | (16.83%) |
| FY2017 | $34.1B | 27.99% |
| FY2016 | $26.6B | 18.67% |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Jun 2026 | $26.2B | 18.36% |
| Mar 2026 | $22.2B | (11.08%) |
| Dec 2025 | $24.9B | (0.02%) |
| Sep 2025 | $24.9B | (0.02%) |
| 42 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| PFE Pfizer Inc. compare | $63.2B |
| AMGN Amgen Inc. compare | $57.3B |
| MRK Merck & Co., Inc. compare | $51.1B |
| NVS Novartis AG compare | $47.1B |
| BMY Bristol Myers Squibb Company compare | $43.1B |
| AZN AstraZeneca PLC compare | $29.5B |
| GILD Gilead Sciences, Inc. | $26.2B |
| GSK GSK PLC Sponsored ADR compare | $24.5B |
| NVO Novo Nordisk A/S compare | $21.8B |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on GILD
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement